Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06801418 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT06801418: Completed Phase 1 study, sponsored by Mirati Therapeutics.
NCT06801418 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 160 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06801418, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a study to evaluate bioequivalence between adagrasib reference tablets and high drug load tablets in healthy adult participants.
Interventions
- DRUG Adagrasib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2025-06-19 |
| Phase | Phase 1 |
What the finished NCT06801418 record still lists
NCT06801418 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (167% higher).
The record links to 0 conditions, and to 1 intervention - of which Adagrasib is the first listed.
NCT06801418 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06801418 about?
NCT06801418 is a clinical study titled "Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets". This is a study to evaluate bioequivalence between adagrasib reference tablets and high drug load tablets in healthy adult participants.
What is the current status of trial NCT06801418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2025-02-04. Estimated completion is 2025-06-19.
What interventions are being tested in trial NCT06801418?
The interventions under investigation include: Adagrasib (DRUG).
Who is sponsoring clinical trial NCT06801418?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06801418's enrollment target sits among peer trials
160 340th of 2000 higher than 1,655 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI